Harry Thomas Hall IV, known as I.V., is the current Managing Director/Chief Executive Officer of Next Science. I.V. has more than 28 years in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. His diverse background and profound understanding of the industry make him the perfect fit to lead Next Science into the future.
I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School.
As the founder and CTO of Next Science, Dr. Matt Myntti oversees and manages all aspects of R&D and product ideation of Next Science technologies. He received his Master’s and Doctoral degrees in Materials Science and Engineering from the University of Dayton and has over 30 granted US patents. Dr. Myntti previously led the biomaterials group at Medtronic Surgical Technologies, which developed novel ENT and neurologic products.
Jon Swanson joined the Next Science team in June 2018 as the Chief Operating Officer to lead our operations, quality and regulatory teams. Mr. Swanson joins us from McKinsey & Co., where as the Head of the Advanced Operations Group, he focused on client operational improvement, product development and quality performance for pharma and medical product industries since 2011.
Prior to that, Mr. Swanson spearheaded manufacturing, product development and operational excellence at Medtronic in multiple leadership roles. As a professional rooted in operations and nuclear engineering excellence, he started his career in the US Navy. He holds a Master’s Degree in Business Administration from the University of Florida and a Bachelor’s Degree in Mathematics from the US Naval Academy.
Marc Zimmerman is the Chief Financial Officer at Next Science. After a 16-year career at Verizon Wireless, which included roles as Vice President of Supply Chain for the Wireless operation, Master Black Belt in the Lean Six Sigma program, and Area CFO for the Northeast Area, he joined Actavo, headquartered in Dublin, Ireland, as the CFO for the US and Caribbean operation. Most recently, he was the CFO for Center for Transportation and the Environment.
Mr. Daniel Canon is the VP, Operations at Next Science. As the former Senior Engineering Manager at Medtronic, he managed strategic company acquisitions, development and execution of subsequent business integration strategies to assure top notch medical device production quality.
An industry veteran with over 20 years of experience, Mr. Canon has lead complex projects in military, commercial, defense and medical operational environments. He has a Bachelor’s Degree in Electrical Engineering from Pennsylvania State University and a Master’s Degree in Mechanical Engineering from the University of Maryland.
Michael Morello is the Vice President of Wound Care Sales for Next Science. Mr. Morello is a graduate of Boston University and brings 25 years of experience in the Medical Device & Pharmaceutical Industries with an extensive focus in both the surgical and wound care sectors. Prior to joining Next Science, Mr. Morello has built and led several successful sales teams in both the commercial and federal spaces.
Jeanne Lee is the Vice President of Regulatory Affairs and Clinical Operations at Next Science. Ms. Lee brings over 20 years of global regulatory experience within the medical device and pharmaceutical industries, gained at leading companies including Hollister Incorporated, Abbott Laboratories and Merck & Co. Inc.. Ms. Lee holds a Master of Science degree in Regulatory Affairs and Quality Assurance from Temple University.
Robert Bell is the Vice President of Surgical Sales for Next Science. Mr. Bell has held various leadership roles within orthopedics, establishing distribution and subsidiaries globally, bringing 14 years of experience in the Medical Device and Orthopedics industries. With Next Science, Mr. Bell oversees the commercial operations via our industry partners and direct sales channels within the surgical sector.
Martyn Jacobs has over two decades of financial services experience, primarily in Equities Research covering emerging industrial companies, including the last decade with a focus on emerging healthcare companies. Mr. Jacobs enjoys detailed fundamental analysis to highlight the primary drivers of long-term economic value. He has a deep understanding of the Australian institutional investor universe and a focus on delivering outstanding client service levels for all stakeholders. Mr. Jacobs holds a Bachelor of Economics with post graduate qualifications in Applied Finance & Investment, as well as Applied Corporate Governance. Recently, Mr. Jacobs completed the AICD Company Directors Course, with membership status.
Many Dedicated Minds, with One Focus in Mind
With diverse, proven experience in research and development and bringing innovative technologies to market, our team has championed medtech innovation through the years. We are committed to improving public health through groundbreaking discoveries and effective solutions that combat antimicrobial resistance caused by biofilms.
Board of Directors
Sharing the same values and goals as everyone at Next Science, the members of our Board of Directors include industry executives with the knowledge, expertise and passion to help guide the company in fulfilling its mission.
Non-Executive Director
Non-Executive Director
Prior to joining Next Science, Aileen was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson’s efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson’s largest medical device acquisition. She also led the efforts to divest the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare (US$16.5 billion), Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. Aileen is a Non-Executive Director of Microbot Medical Inc. (NASDAQ: MBOT)
Harry Thomas Hall IV, known as I.V., is the current Managing Director/Chief Executive Officer of Next Science. I.V. has more than 28 years in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. His diverse background and profound understanding of the industry make him the perfect fit to lead Next Science into the future.
I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School.
Grant was part of Next Science’s ASX listing deal team in 2019. He has been a partner of a major Australian law firm for over fifteen years. Grant has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Grant has been a non-executive director of GLG Corp Ltd (ASX:GLE)(GLG) since 2018 and serves as the Chair of GLG’s Nomination and Remuneration Committee and as a member of GLG’s Audit and Risk Committee. Grant holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. Grant also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan).
Dan is the CEO of iNova Pharmaceuticals (since 2017) which is a leading multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM-North America (with responsibility for a portfolio of businesses spanning Vision Care, Dermatology and Aesthetic Devices) and was also Managing Director, Pacific region. Prior to that, Dan spent over 15 years at Johnson & Johnson Inc in various roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions.